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Abstract
Aims Data on socioeconomic‐related differences in heart failure (HF) care are sparse. Inequality in care may potentially con-
tribute to a poor clinical outcome. We examined socioeconomic‐related differences in quality of HF care among patients with
incident HF with reduced ejection fraction (EF) (HFrEF).
Methods and results We conducted a nationwide population‐based cohort study among patients with HFrEF (EF ≤40%) reg-
istered from January 2008 to October 2015 in the Danish Heart Failure Registry, a nationwide registry of patients with a
first‐time primary HF diagnosis. Associations between individual‐level socioeconomic factors (cohabitation status, education,
and family income) and the quality of HF care defined by six guideline‐recommended process performance measures [New
York Heart Association (NYHA) classification, treatment with angiotensin‐converting‐enzyme inhibitors (ACEI)/angiotensin re-
ceptor blockers (ARB), beta‐blockers and mineralocorticoid receptor antagonists, exercise training, and patient education]
were assessed using multiple imputation and multivariable logistic regression controlling for potential confounders. Among
17 122 HFrEF patients included, 15 290 patients had data on all six process performance measures. Living alone was associated
with lower odds of NYHA classification [adjusted OR (aOR) 0.81; 95% confidence interval (CI): 0.72–0.90], prescription of
ACEI/ARB (aOR 0.76; 95% CI: 0.68–0.88) and beta‐blockers (aOR 0.84; 95% CI: 0.76–0.93), referral to exercise training (aOR
0.75; 95% CI: 0.69–0.81), and patient education (aOR 0.73; 95% CI: 0.67–0.80). Compared with high‐level education,
low‐level education was associated with lower odds of NYHA classification (aOR 0.93; 95% CI: 0.79–1.11), treatment with
ACEI/ARB (aOR 0.99; 95% CI: 0.81–1.20) and beta‐blockers (aOR 0.93; 95% CI: 0.79–1.09), referral to exercise training (aOR
0.73; 95% CI: 0.65–0.82), and patient education (aOR 0.86, 95% CI: 0.75–0.98). An income in the lowest tertile was associated
with lower odds of NYHA classification (aOR 0.67; 95% CI: 0.58–0.79), prescription of ACEI/ARB (aOR 0.80, 95% CI: 0.67–0.95)
and beta‐blockers (aOR 0.88, 95% CI: 0.86–1.01), referral to exercise training (aOR 0.59, 95% CI: 0.53–0.64), and patient ed-
ucation (aOR 0.66; 95% CI: 0.59–0.74) compared with an income in the highest tertile. Overall, no systematic differences were
seen when the analyses were stratified by sex and age groups.
Conclusions Living alone, low‐level education, and income in the lowest tertile were associated with reduced use of recom-
mended processes of HF care among Danish HFrEF patients with a first‐time primary HF diagnosis. Efforts are warranted to
ensure guideline‐recommended HF care to all HFrEF patients, irrespective of socioeconomic background.
Keywords Heart failure with reduced ejection fraction; Inequalities; Performance measures| registry; Social class; Socioeconomic
factors| HFrEF
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Introduction
Worldwide, heart failure (HF) constitutes a major and increas-
ing health burden affecting almost 37 million people.1 The
prevalence of HF is expected to increase substantially in the
future due to the demographic development with ageing
populations, increasing prevalence of cardiovascular risk fac-
tors, and improved survival from ischaemic heart disease.2
Despite improvements in treatment and management in the
last decades, HF is still associated with frequent hospitaliza-
tion, high mortality, and impaired quality of life,3 imposing a
huge economic burden on healthcare systems.4,5
Low socioeconomic status is a strong predictor for the de-
velopment of HF.6 In addition, differences in readmission risk
and mortality according to a level of income and socioeco-
nomic deprivation have been reported in several studies
among patients with HF, even in tax‐financed well‐fare state
settings,7–11 while socioeconomic deprivation, defined with
the Index of Multiple Deprivation 2007, have not been found
to be associated with mortality in one study.12 Socioeconomic
disparities in HF care may potentially contribute to the ob-
served differences in mortality and readmission risk according
to socioeconomic status. However, data on the relationship
between socioeconomic status and HF care are sparse among
patients with HF. We, therefore, performed a nationwide co-
hort study of patients with verified incident HF with reduced
ejection fraction (HFrEF). This study aimed to examine the ef-
fect of individual‐level markers of socioeconomic status on
the quality of HF care among patients with incident HFrEF
in a tax‐financed universal healthcare system with free access
to healthcare services for all citizens.
Methods
This study was based on linked data from the Danish Heart
Failure Registry (DHFR)13 and several other Danish nation-
wide population‐based registries. All Danish residents have
a personal and unique identification number, which enables
direct and accurate linkage of individual‐level information be-
tween public registries.14
Healthcare in Denmark
The Danish healthcare system works across three administra-
tive levels: the state, the regions (five), and the municipalities
(98). The state is responsible for the overall framework for
the provision of health and elderly care, the five regions for
the hospitals, the general practitioners and specialists in
private practice, and the 98 municipalities for primary
healthcare services as well as elderly care.15
Data sources
The DHFR was established in 2003 as a nationwide pro-
gramme to monitor and improve the quality of care for pa-
tients with HF. Evidence‐based performance measures
related to process and outcome of care of incident HF were
defined, and monitoring of fulfilment of the performance
measures has been carried out since 2003. The DHFR includes
data on adult residents with a hospitalization admission or
contact with a hospital cardiology outpatient clinic with a
first‐time primary diagnosis of HF (International Classification
of Diseases, 10th edition; 11.0, I13.0, I13.2, I42.0, I42.6, I42.7,
I42.9, I50.0, I50.1, and 50.9) according to the European Cardi-
ology Society definition of HF.13,16 Patients with previously
verified diagnosis and treatment of HF, isolated right‐sided
HF, and HF secondary to valvular heart disease, non‐correct-
able structural heart disease, or tachycardia‐induced HF are
not included in the DHFR. To ensure the validity of the HF di-
agnosis, the decision to register a patient in the DHFR is made
by a cardiologist. Reporting of data to the registry is manda-
tory for all Danish hospitals treating adult patients with inci-
dent HF.13 The DHFR contains information on HF care as
well as a range of sociodemographic, clinical, and lifestyle‐re-
lated information. Since 2008, data completeness has been
high.13 We obtained data on the process performance mea-
sures (Table 1), age, sex, hospital setting at the time of diag-
nosis (inpatient/outpatient, left ventricular ejection fraction
(LVEF) (<25%, 25% to 35%, >35%), New York Heart Associa-
tion (NYHA) functional classification (I–IV), previous myocar-
dial infarction (yes/no), previous stroke (yes/no), chronic
obstructive pulmonary disease (yes/no), hypertension (yes/
no), diabetes (yes/no), atrial fibrillation (yes/no), S‐creatinine
level ≥150 μmol/L (yes/no), alcohol consumption (>14/21
drinks per week for women and men, respectively), and
smoking (yes/no) from the DHFR.13
The Danish National Patient Registry (DNPR)17 holds ad-
ministrative data (e.g. date of admission and discharge, acute
or elective admission) and diagnoses on all somatic inpatient
hospital contacts from 1977 to 1994; after 1994 also informa-
tion on somatic and psychiatric inpatient, outpatient, and
emergency contacts. Each hospital contact is registered with
a primary diagnosis and one or more secondary diagnoses
(ICD‐8 until 1993 and after that ICD‐10). We used data from
the DNPR to (i) identify patients with previous acute myocar-
dial infarction, stroke, and diabetes, (ii) calculate the modified
Charlson co‐morbidity index (CCI): score for each patient pre-
ceding the diagnosis of HF, excluding points for HF, and (iii)
compute the number of prior inpatient and outpatient hospi-
tal contacts between 1 and 10 years before the HF diagnosis.
We obtained data on vital and migration status during
follow‐up from the Danish Civil Registration System, which
has recorded changes in these variables for all Danish
residents since 1968. Information on vital status is
updated daily.18
3096 I. Schjødt et al.
ESC Heart Failure 2020; 7: 3095–3108
DOI: 10.1002/ehf2.12938
The National Prescription Registry has recorded informa-
tion about prescriptions for drugs dispensed at all Danish
community pharmacies since 1995.19 We used the National
Prescription Registry to identify redeemed prescriptions for
antidepressant and antipsychotic drugs 12 months before
HF diagnosis. Redemption of a prescription was understood
as a gross measure of mental illness or vulnerability.
Statistics Denmark encompasses several registries contain-
ing detailed information on all citizens. The Central Popula-
tion Register contains information on cohabitation status
(household composition) and migration (baseline), with up-
dates every quarter. Each year, since 1973, the Educational
Attainment Register has recorded the highest education
attained for every citizen. Data in the registry are considered
of high validity. Misclassification is reported 0% to 3% by Sta-
tistics Denmark.20 In 2003, the completeness of education in-
formation was 97% in persons aged 15 to 69 years and 75% in
persons aged 70 years or older. The Family Income Register
provides information on family income before tax by the
end of December each year. Data on family income, the
sum of individual incomes of all persons in the family, are
mainly based on information from the Danish tax system.
The Labor Force Statistics, established in 1980, contains infor-
mation on individual‐level labour market affiliation at the end
of November each year. Data on primary affiliation with the
labour market are register‐based and follow the guidelines
of the International Labor Organization. The coverage and va-
lidity of the registry data are deemed to be high.21
Study population
We included patients with incident HFrEF with LVEF ≤ 40%
registered in the DHFR between 1 January 2008 and 31 Octo-
ber 2015. Further, we restricted the study population to (i) in-
patients discharged alive and (ii) outpatients who have been
discharged with HF as a secondary diagnosis within 30 days
before their outpatient visit in order to establish a homoge-
neous HF population. Patient characteristics, for example,
co‐morbidities have been reported to vary depending on
the care setting (inpatient or outpatient) where patients were
first diagnosed with HF.22
We identified inpatients directly from the data obtained
from the DHFR. In addition, we identified those outpatients
with HFrEF who had been hospitalized and discharged with
HF as a secondary diagnosis within 30 days before the regis-
tration in the DHFR by linking patients’ records with informa-
tion from the DNPR.17 A total of 17 214 patients met the
inclusion criteria (Figure 1). Patients with missing data on co-
habitation status and family income were excluded (n = 92).
In order to identify HFrEF with LVEF ≤ 40%, echocardiogra-
phy is required. We, therefore, excluded patients who did not
undergo echocardiography within 6 months before or 7 days
after the date for admission to a hospital or outpatient clinic
or had missing data on echocardiography (n = 946) as well as
patients with missing data on all relevant process perfor-
mance measures (e.g. no answer or date for fulfilment re-
ported) (n = 886). Thus, data from 15 290 patients with
incident HFrEF with LVEF ≤ 40% were available for further
analysis (Figure 1).
Socioeconomic status
Socioeconomic status was assessed based on three
individual‐level markers: cohabitation status, highest educa-
tion attained, and family income. Cohabitation status was
measured as the household composition, that is, all persons
enrolled at the address with their personal identification
number (e.g. single man/woman, married couple/couple,
and households consisting of several families) and catego-
rized as living alone and cohabiting. The highest educational
level attained was categorized according to the International
Standard Classification of education 201123 and divided into
Table 1 Process performance measures in the Danish Heart Failure Registry
Process performance measure LVEF Definition Timeframea
NYHA classification Proportion of patients undergo NYHA classification Within 12 weeksb
ACEI/ARB ≤40% Proportion of patients treated with ACEI/ARB Within 8 weeks
Beta‐blockers ≤40% Proportion of patients treated with beta‐blockers Within 12 weeks
MRA ≤35% Proportion of patients treated with MRA Within 12 weeks
Exercise training ≤40% Proportion of patients started individual exercise training
in a hospital or referred for exercise training in the municipality
after a consultation with a hospital physiotherapistc
Within 12 weeks
Patient education ≤40% Proportion of patients started a structured patient education
(e.g. nutrition, exercise training, understanding medical treatment,
risk factors, and HF symptoms)
Within 12 weeks
Processes of care monitored in the Danish Heart Failure Registry for patients with incident heart failure with reduced ventricular ejection
fraction.
aThe timeframe is defined from the date for admission to either hospital or outpatient clinic.
bThe timeframe for NYHA classification was prolonged from discharge/first outpatient contact to 12 weeks in 2011.
cFrom 2008 to 2010, exercise training should have started in the hospital or in the municipality.
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three educational levels: low‐level education (primary and
lower secondary level), mid‐level education (upper secondary
level), and high‐level education (short‐cycle tertiary, bache-
lor, master, and doctoral or equivalent level). Family income
was measured as the annual gross income for all persons be-
longing to the same family on December 31 of the income
year before the HF diagnosis. Family income was chosen, be-
cause it may better reflect the person’s living conditions and
consumption opportunities than personal income. We
calculated the average yearly family income in the 5 years be-
fore the HF diagnosis. Mean family income was divided into
tertiles of increasing income (low, medium, and high).
Quality of heart failure care
Quality of HF care was assessed using six individual
evidence‐based process performance measures13 monitored
Figure 1 Patient selection flow‐chart. CPR, civil personal registration; DNPR, Danish National Patient registry; ECHO, echocardiography; HF, heart fail-
ure; LVEF, left ventricular ejection fraction.
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in the DHFR for patients with incident HFrEF: NYHA functional
classification (yes/no), pharmacological treatment (yes/no)
with angiotensin‐converting enzyme inhibitors (ACEI) or
angiotensin receptor blockers (ARB), beta‐blockers, and
mineralocorticoid receptor antagonists (MRA), referrals to in-
dividual exercise training (yes/no), and provided a structured
patient education programme (yes/no).13 The process perfor-
mance measures were selected by a multidisciplinary expert
panel to reflect key elements of clinical guideline recommen-
dations on HF care for patients with incident HFrEF (Table 1).
Moreover, the expert panel defined a timeframe for each
process performance measure to capture the timeliness of
the process (Table 1). Further, a composite score defined as
the total number of fulfilled relevant care processes was cal-
culated for each patient. The composite score was divided
into 0–1, 2–3, 4, 5, and 6 performed care processes. Also, a
composite score excluding NYHA classification was computed
and divided into fulfilling 0–1, 2–3, 4, and 5 performance
measures.
Statistical methods
Initially, we described the different patient characteristics for
the overall study population and within each stratum of co-
habitation status, education, and income, respectively. All
variables were presented as frequencies and proportions,
where continuous variables were grouped using appropriate
cut‐offs. Secondly, for each stratum of cohabitation status,
educational level, and family income, we computed the crude
relative risks for fulfilling 2–3, 4, 5, and 6 relevant HF
care processes (six and five performance measures for
LVEF ≤ 35% and LVEF > 35, respectively) compared with
the highest class within each socioeconomic status variable
with the fulfilment of 0–1 performance measures as refer-
ence. The analyses were repeated excluding (i) the NYHA clas-
sification indicator and (ii) patients who died within 90 days
from the first contact to minimize the risk of confounding
by indication. Furthermore, we compared the proportion of
patients fulfilling the individual performance measures ac-
cording to socioeconomic factors. We computed unadjusted
and adjusted odds ratios with 95% confidence intervals using
logistic regression analysis.
We constructed a directed acyclic graph (DAG) for the as-
sociation between income and HF care (Supporting Informa-
tion, Figure S1) using DAGitty24 to identify an appropriate
set of variables to be considered in the analyses. Two ad-
justed models were used. First, we adjusted the crude
odds ratios for age group, sex, NYHA class, CCI score,
co‐morbidities except for chronic obstructive pulmonary dis-
ease, and calendar year. We did not adjust for NYHA class
in the models for the NYHA classification indicator, as these
variables are highly correlated. Secondly, the analyses were
stratified by age group, sex, patient type, and time period
(2008–2010 and 2011–2016) to examine if these covariates
modified the associations. Furthermore, we performed sensi-
tivity analyses with additional adjustment for LVEF, region,
and patient type, as well as mutual adjustment for the re-
maining socioeconomic factors. All variables included in the
analyses were handled as categorical variables.
Our data encompassed low percentages of missing values
(Table 2), and missing data were considered missing at ran-
dom. We used multiple imputation by chained equations25
to account for missing data on educational level and all poten-
tial confounders. Analyses were performed using 20 imputed
datasets. The imputation models for missing data included
all variables with missing data (Table 2), all variables used in
the subsequent analytical models performed (i.e. outcome,
socioeconomic factors, age group, sex, CCI score, myocardial
infarction, stroke, diabetes, calendar year, LVEF, and patient
type and region) as well as auxiliary variables (migration status
at baseline, redeemed prescription of antidepressant or anti-
psychotic medication, number of somatic hospitalizations
within the previous 10 years, and any admission in the last
12 months) predictive of missing values. Multiple imputation
models were performed separately for each process perfor-
mance measure. For comparison, a complete‐case analysis
was performed.
All statistical analyses were performed using Stata 15.1
(StataCorp, 2017, College Station, TX, USA). The study was
approved by the Danish Data Protection Agency (R.no. 1‐
16‐02‐324‐16) and the Danish Clinical Registries and con-
ducted in accordance with the Declaration of Helsinki.26
Results
Socioeconomic factors and composite score for
heart failure care
According to socioeconomic factors, baseline characteristics
are presented in Table 2 and the proportions of all composite
scores according to socioeconomic factors in the Supporting
Information, Table S1. Some correlation between the individ-
ual socioeconomic factors was observed. However, the over-
lap was in general modest, for example, 14% of the study
population was living alone, low‐level educated, and had an
income in the lowest income tertile. Furthermore, 8% of
the study population was cohabiting, had a high‐level educa-
tion, and an income in the highest income tertile.
Figure 2 shows the relative chance of fulfilling the six
processes of HF care according to the individual socioeco-
nomic factors. We found that patients living alone, with a
low‐level education, in the lowest and medium‐income
tertiles received poorer quality of care defined as the fulfil-
ment of six process performance measures of HF care. The
same pattern was observed in analyses when (i) excluding
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the NYHA classification indicator and (ii) excluding patients
who died within 90 days of the first contact (Supporting Infor-
mation Table S1).
Socioeconomic factors and individual processes
of heart failure care
The proportions of patients who received HF care that ful-
filled the specific process performance measures are pre-
sented in the Supporting Information, Table S2. The highest
percentage was observed for treatment with ACEI in all
strata, cohabitation status, education and income, and
ranged from 90.8% (living alone) to 94.6% (highest income
tertile). The lowest proportion was observed for the referral
to exercise training of 19.3% (lowest income tertile) and
35.6% (highest income tertile).
All logistic regression analyses for the individual process
performance measures, in relation to socioeconomic factors,
are presented in the Supporting Information, Table S3. The
adjusted analyses showed that patients living alone were less
likely to receive all processes of HF care, except treatment
with MRA (Figure 3) compared with patients cohabiting. Living
alone was associated with a higher chance of being prescribed
MRA. However, the association was not statically significant.
Compared with patients with high‐level education, patients
with low‐level education had a lower chance of being NYHA
classified, prescribed ACEI/ARB and beta‐blocker therapy, re-
ferred to exercise training, and receiving patient education
but had a higher chance of being prescribed MRA therapy.
However, only the education‐related differences in MRA ther-
apy, exercise training, and patient education were statistically
significant (Figure 3). Associations between mid‐level educa-
tion and fulfilling of the performance measures for HF care
followed the same pattern as for low‐level education, but no
statistical significance was observed for exercise training. Pa-
tients in the lowest income tertile were less likely to be NYHA
classified, to be treated with ACEI/ARB and beta‐blockers, to
be referred to exercise training, and to receive a structured
patient education programme; they were, however, more
likely to receive MRA therapy compared with patients in the
highest income tertile. All associations were statistically signif-
icant, except with beta‐blocker treatment (Figure 4). Medium
income tertile was associated with a lower chance of being
NYHA classified, treated with ACEI/ARB, referred to exercise
training, and receiving patient education; however, the associ-
ation with ACEI/ARB treatment was not statistically signifi-
cant. Similarly, no statistically significant differences were
observed for beta‐blocker and MRA, although patients in the
medium‐income tertile had a higher chance of MRA treat-
ment compared with patients in the highest income tertile.
Overall, no systematic differences were seen when the analy-
ses were stratified by sex, age groups, inpatient versus outpa-
tient status, and years 2008 to 2010 versus 2011 to 2015 (dataTa
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not shown). After full adjustment (sensitivity analysis), living
alone remained statistically significantly associated with a
lower prescription of ACEI/ARB, beta‐blockers, and less pa-
tient education. Low‐level education persisted statistically sig-
nificantly associated with less referral to exercise training, and
lowest income tertile remained statistically significantly asso-
ciated with less NYHA classification, referral to exercise train-
ing, and receiving patient education.
Discussion
Our results showed significant socioeconomic status‐related
differences in the quality of HF care among patients with ver-
ified incident HFrEF in Denmark. Living alone, low educational
level, and lowest income tertile were associated with a
poorer quality of care defined as lack of implementation of
evidence‐based guideline‐recommend processes of HF care.
In particular, documented NYHA classification, being provided
exercise training, and structured patient education pro-
gramme varied by socioeconomic factors. We observed that
patients living alone were less likely to be treated with
ACEI/ARB and beta‐blockers, and patients in the lowest in-
come tertile were less likely to be prescribed treatment with
ACEI/ARB.
Socioeconomic factors and composite scores for
process performance measures
The most substantial differences were found for patients in
the lowest income tertile, where the RR of receiving all six rel-
evant processes of HF care was 0.63 compared with patients in
the highest income tertile. A similar pattern was observed for
the medium income tertile, low‐level education, and living
alone. Inequity in HF care place socially deprived patients with
HFrEF at double risk. Low socioeconomic status is a substantial
risk factor of developing HF,6 and recent studies indicate
that income, poverty, and employment status is associated
with a poor clinical outcome, for example, mortality and
readmission among patients after being diagnosed with HF in
universal healthcare systems.7–10,27 Some studies have shown
a relationship between HF care processes delivered (e.g.
ACEI/ARB) andmortality and readmission among patients with
HF, while other studies have not found this association.28,29
Further, there may be a dose–response association between
the fulfilment of performance measures and mortality.30
Our analyses revealed a gap in the quality of HF care pro-
vided by the Danish Healthcare system regardless of the
causal mechanisms. We demonstrated that living alone was
associated with a lower chance of receiving all HF care pro-
cesses except treatment with MRA. One possible explanation
for this finding may be that living alone is associated with less
likelihood of planned follow‐up in specialized HF clinics31 pro-
viding evidence‐based HF treatment, patient education, and
referral for exercise training. Living/marital status is often
considered a proxy for the level of social support delivered
by a spouse or partner, family, or friends. Lack of social sup-
port might negatively impact patients’ eagerness, motivation,
and adherence to such a follow‐up programme.
Cohabitation status is not the most frequently used mea-
sure of socioeconomic status. However, cohabitation status
has been considered an important socioeconomic factor,
and living alone is also often associated with a lower income.
However, after adjusting for additional potential variables in-
cluding income and education, living alone remained associ-
ated with a lower chance of treatment with ACEI/ARB,
Figure 2 The relative chance for fulfilment of six process performance measures compared with fulfilment of 0–1 process performance measures ac-
cording to socioeconomic factors.
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beta‐blockers, and receiving patient education. Thus, our
study supports the importance of including an assessment
of cohabitation status when investigating equity in healthcare
among patients with HFrEF. Lack of social support may con-
tribute to poorer clinical outcomes among socioeconomically
deprived patients with HF.
Socioeconomic factors and medical treatment
To the best of our knowledge, our study is the first to exam-
ine the impact of socioeconomic factors on the adherence to
evidence‐based, guideline‐directed medical therapy in pa-
tients with incident HFrEF in a tax‐financed healthcare
Figure 3 Adjusted odds ratios for fulfilled performance measures for heart failure care according to (A) cohabitation status and (B) educational level.
Variables used for adjustment included sex, age groups, NYHA class, Charlson co‐morbidity score, myocardial infarction, stroke, hypertension, diabetes,
atrial fibrillation, S‐creatinine ≥150 μmol/L and calendar year. aNo adjustment for NYHA class. bLeft ventricular ejection fraction ≤ 35%. ACEI/ARB,
angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart
Association.
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system. Most previous studies have primarily examined pre-
scription or dispensation of ACEI/ARB, beta‐blockers, and
MRA among patients with HF irrespective of LVEF in hospital,
outpatient, and primary care settings. Except for four
studies,11,12,32,33 most previous studies are based on older
data collected at a time when patients with HF were not rou-
tinely treated with ACEI/ATII‐inhibitors, beta‐blockers, and
MRA.34–38 Thus, these ‘early’ studies may not be of relevance
to current HF care.
We found an income‐related difference in treatment with
ACEI/ARB but not with beta‐blockers. Unexpectedly, low in-
come patients were more likely to be treated with MRA. Our
findings regarding ACEI/ARB and MRA are contrary to previ-
ous studies. Two large Swedish studies,32,33 reporting low in-
come to be associated with a higher ACEI dispensation after
hospitalization for HF32 and a lower rate of MRA prescription
among patients with HFrEF and HF duration ≥6 months from
the Swedish HF registry,33 respectively, compared with
high‐income patients. Contrary to our results, a UK study in-
cluding 1802 outpatients with stable HF (LVEF ≤45%) for
3months, treated with state of the art therapies in cardiology
outpatient clinics, found comparable doses of prescribed
ACEI/ARB and beta‐blockers across deprivation quintiles.11
Similarly, a large community study in the UK observed no dif-
ferences in ACEI/ARB, beta‐blockers, and MRA treatment
between the most affluent and the most deprived patients
with chronic HF.12 It is particularly noteworthy with these con-
trary findings in two similar Scandinavian countries. However,
differences in HF populations, organizational structure for HF
management, and measurements used for socioeconomic sta-
tus as well as for HF treatment may explain some of the differ-
ences in the results. Both UK studies used indicators of
socioeconomic status based on area‐level deprivation, which
may lead to considerable misclassification of individual socio-
economic status. Thereby, the unadjusted association may be
underestimated.39 Moreover, the HF population by Witte
et al. included outpatients with stable HF; thus, study popula-
tion selection may have been related to the socioeconomic
status of the patients and their HF treatment. A Swedish study
has shown that patients with HF with planned follow‐up in HF
clinics were more likely treated with ACEI/ARB, beta‐blockers,
and MRA, married or cohabitating, with higher education and
income. However, education and income were not statistically
significantly associated in the adjusted analyses. Our results
are inconclusive, and income was not consistently associated
with prescribed guideline‐recommend first‐line medical ther-
apy among incident patients with HFrEF.
We did not find any impact of educational level on treat-
ment with ACEI/ARB, beta‐blockers, and MRA, which corrobo-
rate findings in the two other Swedish studies.32,33 Our study
Figure 4 Adjusted odds ratios for fulfilled performance measures for heart failure care according to income. Variables used for adjustment included
sex, age groups, NYHA class, Charlson co‐morbidity score, myocardial infarction, stroke, hypertension, diabetes, atrial fibrillation, S‐
creatinine ≥ 50 μmol/L and calendar year. aNo adjustment for NYHA class. bLeft ventricular ejection fraction ≤ 35%. ACEI/ARB,
angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart
Association.
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demonstrated that living alone was associated with a lower
prescription of ACEI/ARB and beta‐blockers but not MRA. Sim-
ilar results for MRA have been reported previously.33 Overall,
treatment with MRA did not appear to be particularly affected
by socioeconomic variation, which may be explained by the
fact that MRA is recommended for a select group of patients.
Further, the MRA indicator was implemented in late 2007.
Therefore, special attention may have been paid to providing
this standardized treatment.
Some patients might have started treatment with
ACEI/ARB, beta‐blockers, and MRA after the defined
timeframe, although early initiation of therapy is considered
essential. Studies have reported that eligible patients with
HFrEF who did not fulfil performance measures for treatment
with ACEI/ARB and beta‐blocker at hospital discharge were
less likely to receive treatment within 60–90 days post‐
discharge.40,41
Socioeconomic factors and exercise training and
patient education
In this study, 80.3% and 27.1%, respectively, of all patients
newly diagnosed with HFrEF received structured patient edu-
cation and were referred to supervised individual exercise
training within the defined timeframe. After adjustment, we
found that patients living alone, with a low‐level education
and lower incomes, were less likely to receive patient educa-
tion and be referred to individual exercise training compared
with patients cohabiting, with a high‐level education, and
with a high income. Thus, age, sex, symptom severity, and
co‐morbidity did not explain the association between socio-
economic factors and the delivered HF care. Existing studies
report that low socioeconomic status patients are often less
likely to be informed, willing to participate, and referred to
cardiac rehabilitation.42–44 Barriers to cardiac rehabilitation,
for example, distance, costs, transportation issues, and lack
of energy, have been reported to be more pronounced in pa-
tients with a low subjective financial status compared with
those with a high subjective financial status.44 Furthermore,
it is known that the healthcare professionals’ endorsement
of and attitude towards cardiac rehabilitation are positively
associated with referral to rehabilitation.43 A recent Swedish
study found that being married/cohabiting was associated
with planned referral to follow‐up in nurse‐led HF clinics
among inpatients and outpatients with HF, while no associa-
tions were found for level of education and income.31
Increased awareness of barriers in low socioeconomic sta-
tus patients among clinicians regarding exercise training and
patient education in patients with HFrEF seems necessary.
New tools and approaches are needed to ensure equity in
HF care and should also be addressed in strategies for the im-
plementation of clinical guidelines.
Based on the results in the present study, healthcare sys-
tems responsible for treating patients with HFrEF should pay
more attention to, explore and target efforts concerning po-
tential barriers at an organization, provider and patient levels
that impede high‐quality care for incident HFrEF patients liv-
ing alone, with a low‐level education and with a low family
income. Moreover, our study suggests a need to monitor pro-
cess performance measures according to socioeconomic sta-
tus to ensure equitable care for all patients. Two previous
studies have reported conflicting results regarding the link be-
tween socioeconomic deprivation and risk of death among
patients with HF receiving equitable treatment with HF
medication.11,12 Thus, it remains uncertain whether observed
socioeconomic status‐related differences in HFrEF care affect
clinical outcomes following an HFrEF diagnosis. Such knowl-
edge would be beneficial for developing healthcare strategies
to reduce socioeconomic status‐related differences in clinical
outcomes.
Strengths and limitations
The strengths of our study are the use of a nationwide
population‐based design, prospectively recorded individual‐-
level data, and the large sample of patients with a confirmed
and well‐defined diagnosis of HFrEF in a universal
tax‐financed healthcare system. Moreover, we were able to
cover different domains of HF care (prognosis, medical treat-
ment, patient education, and exercise training) and to link
guideline‐recommended processes of HF care and
individual‐level socioeconomic data, which in many interna-
tional healthcare systems is impossible. However, the study
was carried out in a universal healthcare system, which may
limit the application of the results to other types of
healthcare systems. Our study was based on data collected
during routine clinical practice. This way of collecting data
may potentially impact on the accuracy of the data collected.
However, extensive efforts have been invested in ensuring
completeness and data accuracy in the DHFR.13 In addition,
information about the NYHA class was measured within a
12‐week timeframe from admission or first outpatient con-
tact. Thus, there is a potential risk of misclassification in the
NYHA class used for adjustment in analyses in this study.
In this study, we used multivariable adjustment, stratifica-
tion, and multiple imputation to take potential confounding
into account. We observed no important differences between
the results when the unadjusted and adjusted analyses were
restricted to patients with complete information on all covar-
iates. However, there is a risk of residual confounding due to
lack of data, for example, information on contraindications to
the recommended anti‐congestive therapy and patient pref-
erences, which may have affected our results. In addition,
data on physiological variables that are often important
drivers in the clinical decision making, including blood
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pressure and heart rate, could potentially further have im-
proved our insights into the underlying mechanisms in our
analysis. However, lack of these data is unlikely to have bi-
ased our results because these variables are more likely to
be mediators between socioeconomic status and prescription
of HF medication rather than confounding factors.45
Conclusions
Living alone, low‐level education, and lower‐income levels
were associated with a lower chance of being referred for ex-
ercise training and receiving patient education among pa-
tients in a universal tax‐financed healthcare system newly
diagnosed with HFrEF. Thus, low socioeconomic status pa-
tients may be at double risk: first of all, to develop HF and
secondly, to receive suboptimal HF care. Sustained and out-
reach efforts are needed to ensure the delivery of equitable
care among patients with incident HFrEF.
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